CLOVIS ONCOLOGY INC's ticker is and the CUSIP is 189464AC4. A total of 30 filers reported holding CLOVIS ONCOLOGY INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $367,000 | -2.9% | 500,000 | 0.0% | 0.00% | – |
| Q1 2021 | $378,000 | -45.5% | 500,000 | -50.0% | 0.00% | – |
| Q4 2020 | $694,000 | -0.9% | 1,000,000 | 0.0% | 0.00% | – |
| Q3 2020 | $700,000 | -40.9% | 1,000,000 | -48.9% | 0.00% | -100.0% |
| Q2 2020 | $1,185,000 | +2.5% | 1,957,000 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $1,156,000 | -45.5% | 1,957,000 | -42.1% | 0.00% | 0.0% |
| Q4 2019 | $2,121,000 | +1.4% | 3,382,000 | -32.5% | 0.00% | 0.0% |
| Q3 2019 | $2,092,000 | +58.2% | 5,007,000 | +135.6% | 0.00% | 0.0% |
| Q2 2019 | $1,322,000 | -20.2% | 2,125,000 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $1,657,000 | -53.8% | 2,125,000 | -58.5% | 0.00% | -66.7% |
| Q4 2018 | $3,586,000 | -71.9% | 5,125,000 | -68.9% | 0.00% | -25.0% |
| Q3 2018 | $12,754,000 | +6.5% | 16,500,000 | +26.9% | 0.00% | +33.3% |
| Q2 2018 | $11,971,000 | – | 13,000,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Jabre Capital Partners S.A. | 3,500,000 | $2,732,000 | 0.90% |
| SHENKMAN CAPITAL MANAGEMENT INC | 8,721,000 | $6,769,000 | 0.82% |
| CAMDEN ASSET MANAGEMENT L P /CA | 32,275,000 | $24,949,000 | 0.70% |
| PFM Health Sciences, LP | 57,632,000 | $44,730,000 | 0.66% |
| Partner Investment Management, L.P. | 768,000 | $596,000 | 0.46% |
| SYMPHONY ASSET MANAGEMENT LLC | 1,000,000 | $776,000 | 0.21% |
| SSI INVESTMENT MANAGEMENT LLC | 3,000,000 | $2,319,000 | 0.18% |
| PointState Capital LP | 12,000,000 | $9,342,000 | 0.12% |
| MIZUHO SECURITIES USA LLC | 2,000,000 | $1,548,000 | 0.12% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 2,000,000 | $1,546,000 | 0.11% |